What Pharma Can Learn From Military Intelligence
August 21, 2026
Former military intelligence officer Tony Page discusses what pharma can learn from early warning systems, decision cycles, and the discipline of intelligence
5 min read
False
The voices driving change and progress in medicine making. Explore stories, interviews, and community highlights that inspire and inform.
Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine
View Profile
Claudia Zylberberg discusses building the infrastructure, partnerships, and policies needed to bring advanced therapies to patients at scale
All the latest Medicine Maker articles.
August 17, 2026
PRAME-targeted T cells produce a complete response in metastatic nephroblastoma, CAR T cells remain active after a decade, and an in vivo CRISPR screen identifies edits that strengthen solid-tumor activity
3 min read
August 14, 2026
John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors
4 min read
August 13, 2026
Alexander Seyf on why the UK is losing ground in cell and gene therapy, the real bottlenecks to commercialization, and why digitalization is no longer optional
8 min read
August 12, 2026
NurExone CEO Lior Shaltiel discusses the company’s exosome-based approach to nerve regeneration, the manufacturing hurdles facing the field, and what it will take to bring nanotechnology therapeutics to patients
11 min read
August 11, 2026
Ann Cleves on why the future of small-molecule drug discovery lies beyond the rule of five
3 min read
August 10, 2026
Why early process development, analytical planning, and tech transfer can shape the future of cell and gene therapy manufacturing
5 min read
August 10, 2026
Johnson & Johnson partners with Sail Biomedicines, an FDA advisory committee votes against deramiocel for Duchenne cardiomyopathy, and researchers uncover factors influencing CAR T and CAR NK outcomes
3 min read
August 6, 2026
Samsung Biologics’ Sojeong Lee discusses why biologics developers are paying closer attention to glycosylation earlier in development.
7 min read
August 6, 2026
Six drug development leaders discuss smarter immunotherapy combinations, the enduring potential of small molecules, emerging modalities, and how cancer treatment could evolve over the next two decades
8 min read
August 5, 2026
In part two of our conversation, Lingshi Tan explores how China’s integrated biopharma ecosystem is reshaping assumptions about speed, cost, innovation, and cross-border clinical development
14 min read
False